UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 197

Sortiert nach

Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review

World journal of urology, 2020-03, Vol.38 (3), p.601-611

2020

Link zum Volltext

Verfügbarkeit prüfen

Peri‐operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score‐weighted European multicentre study

BJU international, 2018-01, Vol.121 (1), p.101-110

2018

Link zum Volltext

Verfügbarkeit prüfen

Renal transplantation in urinary diversions

Urologe. Ausgabe A, 2020-01, Vol.59 (1), p.27

2020

Link zum Volltext

Verfügbarkeit prüfen

Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting

European urology open science (Online), 2020-07, Vol.19, p.e830

2020

Link zum Volltext

Verfügbarkeit prüfen

Intrinsic molecular urothelial cancer subtypes remain stable during metastatic evolution

European urology, 2023-02, Vol.83, p.S1690-S1691

2023

Link zum Volltext

Verfügbarkeit prüfen

A1171 - Intrinsic molecular urothelial cancer subtypes remain stable during metastatic evolution

European urology, 2023-02, Vol.83, p.S1690-S1691

2023

Link zum Volltext

Verfügbarkeit prüfen

Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders

European urology, 2021-06, Vol.79, p.S644

2021

Link zum Volltext

Verfügbarkeit prüfen

A0861 - Molecular characterization of upper urinary tract urothelial carcinoma and paired bladder cancer recurrences

European urology, 2024-03, Vol.85, p.S1896-S1897

2024

Link zum Volltext

Verfügbarkeit prüfen

Molecular characterization of upper urinary tract urothelial carcinoma and paired bladder cancer recurrences

European urology, 2024-03, Vol.85, p.S1896-S1897

2024

Link zum Volltext

Verfügbarkeit prüfen

A1168 - Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition

European urology, 2023-02, Vol.83, p.S1686-S1687

2023

Link zum Volltext

Verfügbarkeit prüfen

Protein-based molecular subtypes associate with clinical-pathological characteristics in a multi-institutional cohort of upper tract urothelial carcinomas

European urology, 2023-02, Vol.83, p.S1693-S1694

2023

Link zum Volltext

Verfügbarkeit prüfen

Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition

European urology, 2023-02, Vol.83, p.S1686-S1687

2023

Link zum Volltext

Verfügbarkeit prüfen

A1173 - Protein-based molecular subtypes associate with clinical-pathological characteristics in a multi-institutional cohort of upper tract urothelial carcinomas

European urology, 2023-02, Vol.83, p.S1693-S1694

2023

Link zum Volltext

Verfügbarkeit prüfen

Bladder tumor subtype commitment occurs in carcinoma in-situ driven by key signaling pathways including ECM remodeling

European urology, 2021-06, Vol.79, p.S640

2021

Link zum Volltext

Verfügbarkeit prüfen

944P - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods

Annals of oncology, 2019-10, Vol.30, p.v380-v380

2019

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods

Annals of oncology, 2019-10, Vol.30, p.v380

2019

Link zum Volltext

Verfügbarkeit prüfen

941P - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

Annals of oncology, 2019-10, Vol.30, p.v378-v379

2019

Link zum Volltext

Verfügbarkeit prüfen

933P - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

Annals of oncology, 2019-10, Vol.30, p.v375-v376

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

Annals of oncology, 2019-10, Vol.30, p.v378-v379

2019

Link zum Volltext

Verfügbarkeit prüfen

Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

Annals of oncology, 2019-10, Vol.30, p.v375-v376

2019

Link zum Volltext

Verfügbarkeit prüfen

Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders

Urologic oncology, 2020-12, Vol.38 (12), p.907-907

2020

Link zum Volltext

Verfügbarkeit prüfen

Divergent immunobiological correlates of FDA-/EMA-approved PD-L1 assays and scoring algorithms in muscle-invasive bladder cancer

Urologic oncology, 2020-12, Vol.38 (12), p.908-908

2020

Link zum Volltext

Verfügbarkeit prüfen

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer

Cancer management and research, 2021-01, Vol.13, p.6567-6578

2021

Link zum Volltext

Verfügbarkeit prüfen

Side effect management of tyrosine kinase inhibitors in urology : Hypertension

Urologe. Ausgabe A, 2016-07, Vol.55 (7), p.952

2016

Link zum Volltext

Verfügbarkeit prüfen

Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects

Urologe. Ausgabe A, 2016-06, Vol.55 (6), p.805

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 197

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(159)
Mit Volltextzugriff
(171)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review

Peri‐operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score‐weighted European multicentre study

Renal transplantation in urinary diversions

Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting

Intrinsic molecular urothelial cancer subtypes remain stable during metastatic evolution

A1171 - Intrinsic molecular urothelial cancer subtypes remain stable during metastatic evolution

Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders

A0861 - Molecular characterization of upper urinary tract urothelial carcinoma and paired bladder cancer recurrences

Molecular characterization of upper urinary tract urothelial carcinoma and paired bladder cancer recurrences

A1168 - Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition

Protein-based molecular subtypes associate with clinical-pathological characteristics in a multi-institutional cohort of upper tract urothelial carcinomas

Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition

A1173 - Protein-based molecular subtypes associate with clinical-pathological characteristics in a multi-institutional cohort of upper tract urothelial carcinomas

Bladder tumor subtype commitment occurs in carcinoma in-situ driven by key signaling pathways including ECM remodeling

944P - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods

Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods

941P - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

933P - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders

Divergent immunobiological correlates of FDA-/EMA-approved PD-L1 assays and scoring algorithms in muscle-invasive bladder cancer

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer

Side effect management of tyrosine kinase inhibitors in urology : Hypertension

Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects

Suchergebnisse filtern